Professional Reference articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
Jaundice in pregnancy, whilst relatively rare, has potentially serious consequences for maternal and fetal health. It can be caused by pregnancy or occur intercurrently. Causes of jaundice specific to pregnancy include:
- Pre-eclampsia associated with HELLP syndrome (= haemolysis, elevated liver enzymes and low platelet count).
- Acute fatty liver of pregnancy.
- Hyperemesis gravidarum.
- Intrahepatic cholestasis of pregnancy.
The presenting clinical features of liver disease in pregnancy are often nonspecific and consist of jaundice, nausea, vomiting and abdominal pain. All liver diseases occurring during pregnancy can lead to increased maternal and fetal morbidity and mortality.[2, 3]
Acute viral hepatitis
Viral hepatitis is the most common cause of jaundice in pregnancy with infections due to hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E viruses.
The incidence of hepatitis in pregnancy varies greatly around the world; in developed countries the incidence is around 0.1%, whilst in developing countries it can range from 3-20% or higher.
The course of most viral hepatitis infections is unaltered by pregnancy - the exception is hepatitis E, where pregnant women who contract the disease exhibit fatality rates of 10-20%.
See the separate Hepatitis A article for further details.
- Isolate the infected patient to prevent spread.
- Symptomatic treatment includes maintenance of adequate hydration and nutrition.
- Pregnant women exposed to the virus can be given immune globulin within two weeks of exposure, together with vaccine.
- It is not clear if the virus is transmitted from mother to baby but, if the illness has occurred in the final month of pregnancy, the neonate should receive immune globulin.
See the separate Hepatitis B article for further details.
- This is the most common cause of acute viral hepatitis in pregnancy and can occur in acute, subclinical or chronic form.
- The presence of HBeAg is associated with a very high risk of neonatal infection.
- All women should now be offered hepatitis B screening as part of routine antenatal screening.
- Infants of HBsAg-positive women should receive hepatitis B immune globulin immunoprophylaxis at birth and hepatitis B vaccine at 1 week, 1 month and 6 months of age. This regime reduces the incidence of hepatitis B vertical transmission to less than 3%.
- The prevalence of neonatal infection depends on the time during gestation that maternal infection takes place: rare in the first trimester, 6% in the second trimester and 67% of those in the third trimester.
See the separate Hepatitis C article for further details.
- No therapy has been shown to influence the neonatal transmission of hepatitis C virus.
- Interferon should not be used during pregnancy because of possible adverse effects on the fetus.
This develops as a co-infection with hepatitis B. When present, it increases the incidence of acute hepatic failure.
- This is rare in the developed world but, in developing countries (where it is more common), it is responsible for a high level of fulminant hepatic failure and mortality in pregnant women.
- In India it appears to be associated with a higher maternal mortality rate and worse obstetric and fetal outcomes compared with other causes of acute viral hepatitis in pregnancy.
Cholelithiasis in pregnancy
Symptomatic gallstone disease is the second most common abdominal emergency in pregnant women.
This may affect as many as 6% of pregnant women but jaundice occurs only in about 1 in 20 of these women. Pregnancy alters bile composition and gallbladder emptying slows in the second trimester, increasing the risk of gallstones.
Individual risk factors are multiparity and previous gallbladder disease.
Symptoms are similar in pregnant and non-pregnant women:
- Pain in the right upper quadrant or epigastrium, peaking at 12-24 hours.
- Pain may radiate towards the back and there may be epigastric or right upper-quadrant tenderness. Murphy's sign (right-sided tenderness at the tip of the 9th costal cartilage as the patient breathes in) is much less common in pregnancy.
Obstructive jaundice requires surgical intervention, usually via laparoscopic cholecystectomy. There is an associated fetal loss of approximately 6%.
Chronic liver disease
Chronic liver disease in pregnancy is associated with an increased risk of fetal loss:
- In patients with primary biliary cirrhosis (PBC), ursodeoxycholic acid can be safely continued. Cholestasis may worsen during pregnancy with PBC.
- Infants of patients with marked hyperbilirubinaemia during pregnancy may require exchange transfusion at birth.
Autoimmune hepatitis can present with an acute attack. Serum bilirubin increase depends on:
- Type of disease.
- Presence of antinuclear, small muscle, liver-kidney microsomal antibodies or antibodies to soluble liver antigen/liver pancreas antibodies.
Azathioprine treatment has been used during pregnancy. There is generally a favourable prognosis for both mother and baby.
Pre-eclamptic liver disease and HELLP
See the separate HELLP Syndrome article for further details.
This complicates 3-10% of pre-eclamptic pregnancies and the risk of recurrence in future pregnancies is 3-4%.
The most effective treatment for HELLP is prompt delivery.
Acute fatty liver of pregnancy
- It is a rare condition with an incidence of 5 in 100,000 pregnancies.
- Acute fatty liver of pregnancy (AFLP) tends to occur in late pregnancy.
- Risk factors include first pregnancies, pre-eclampsia, twin pregnancies and male fetuses.
- It may be associated with a mutant gene producing a defect in mitochondrial fatty acid oxidation and infants born to mothers with AFLP should be screened for defects in this system.
This usually presents acutely with nausea, vomiting and abdominal pain, fevers, headache and pruritus, beginning typically at about 35 weeks of gestation but can occur much earlier. It may also appear immediately after delivery.
Jaundice appears soon after onset of symptoms and can become intense in a large proportion of patients. Fulminant liver failure may follow.
- The white cell count is often elevated. There may also be neutrophilia and thrombocytopenia.
- Liver transaminases are moderately high.
- Raised serum bilirubin.
- Abnormal clotting with coagulopathy (prolongation of prothrombin and partial thromboplastin times with depression of fibrinogen levels).
Biopsy would be diagnostic but coagulation problems often preclude it. CT/MRI scanning may show reduced attenuation in the liver.
Consider early delivery, as the condition usually resolves afterwards with complete recovery. Supportive ITU care is frequently required.
AFLP is a life-threatening condition with a reported 1.8% maternal and 23% fetal mortality rate.Serious complications include:
- Disseminated intravascular coagulation (DIC) and gastrointestinal bleeding.
- Hepatic coma.
- Acute kidney injury.
Intrahepatic cholestasis of pregnancy
Intrahepatic cholestasis is defined as pruritus with elevated serum bile acids occurring in the second half of pregnancy, which resolves after delivery. See also the separate article on Obstetric Cholestasis.
- The incidence in Europe ranges from 0.1% to 1.5% of pregnancies but there is increased prevalence in South America and Scandinavia.
- Pathogenesis remains unclear but is related to abnormal biliary transport across the canalicular membrane. Direct effects of female sex hormones induce cholestasis and inhibit the bile salt export pump. This is supported by the fact that women with a history of intrahepatic cholestasis of pregnancy (ICP) are prone to cholestasis induced by oral contraceptives and vice versa.
The main symptom is pruritus, especially of the palms and soles, which is followed by generalised symptoms. This usually occurs from week 25 of gestation.
Jaundice is uncommon. However, when present, it arises 2-4 weeks after the onset of pruritus.
- Aminotransferase activity can be increased by 20 times the normal level.
- Raised gamma-glutamyltransferase activity is unusual but is indicative of MDR3 mutation or underlying liver disease unrelated to pregnancy. The key diagnostic test is a fasting serum bile acid concentration of greater than 10 mmol/L.
Ursodeoxycholic acid provides relief against pruritus, and improved LFTs; it is well tolerated both by mother and fetus.
Maternal morbidity is low. The importance of this disorder is the effects on the fetus. It can lead to chronic placental insufficiency which may result in anoxia, prematurity, perinatal death, fetal distress and stillbirth. ICP often recurs in subsequent pregnancies.
Did you find this information useful?
Further reading & references
- Hay JE; Liver disease in pregnancy. Hepatology. 2008 Mar 47(3):1067-76.
- Lata I; Hepatobiliary diseases during pregnancy and their management: An update. Int J Crit Illn Inj Sci. 2013 Jul 3(3):175-82. doi: 10.4103/2229-5151.119196.
- Goel A, Jamwal KD, Ramachandran A, et al; Pregnancy-related liver disorders. J Clin Exp Hepatol. 2014 Jun 4(2):151-62. doi: 10.1016/j.jceh.2013.03.220. Epub 2013 Mar 16.
- Patra S, Kumar A, Trivedi SS, et al; Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann Intern Med. 2007 Jul 3 147(1):28-33.
- Navaneethan U, Al Mohajer M, Shata MT; Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int. 2008 Nov 28(9):1190-9. Epub 2008 Jul 25.
- Corneille MG, Gallup TM, Bening T, et al; The use of laparoscopic surgery in pregnancy: evaluation of safety and efficacy. Am J Surg. 2010 Sep 200(3):363-7.
- Date RS, Kaushal M, Ramesh A; A review of the management of gallstone disease and its complications in Am J Surg. 2008 Oct 196(4):599-608. Epub 2008 Jul 9.
- Joshi D, James A, Quaglia A, et al; Liver disease in pregnancy. Lancet. 2010 Feb 13 375(9714):594-605.
- Pusl T, Beuers U; Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis. 2007 May 29 2:26.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.